

# CITATION REPORT

List of articles citing

**Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition**

**DOI: 10.1097/00007691-200404000-00009**

**Therapeutic Drug Monitoring, 2004, 26, 137-44.**

**Source:** <https://exaly.com/paper-pdf/37721731/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
349	Serotonin neurotoxins--past and present. <b>2004</b> , 6, 589-614		39
348	Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. <b>2004</b> , 25, 505-8		140
347	3,4-methylenedioxyamphetamine (MDMA) intoxication in an infant chronically exposed to cocaine. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 409-11	3.2	22
346	Ecstasy for intimacy: potentially fatal choices for adolescents and young adults: update for the clinical nurse specialist. <b>2005</b> , 19, 63-4		3
345	Metabolism of Drugs of Abuse: Its Contribution to the Toxicity and the Inter-Individual Differences in Drug Sensitivity. <b>2005</b> , 51, 1-7		7
344	Increased responsiveness to MDMA in adult rats treated neonatally with MDMA. <b>2006</b> , 28, 95-102		12
343	MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. <b>2005</b> , 61, 551-4		42
342	Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. <b>2005</b> , 313, 422-31		105
341	Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA. <b>2005</b> , 51, 1811-22		47
340	Drug interactions in the management of HIV infection. <b>2005</b> , 6, 233-53		13
339	Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. <b>2006</b> , 41, 1551-601		164
338	Effects of (+/-)3,4-methylenedioxyamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. <b>2006</b> , 142, 515-25		34
337	Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. <b>2006</b> , 7, 1671-80		22
336	Influence of CYP2D6 polymorphism on 3,4-methylenedioxyamphetamine ('Ecstasy') cytotoxicity. <b>2006</b> , 16, 789-99		36
335	Assessment of chronic exposure to MDMA in a group of consumers by segmental hair analysis. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 106-9	3.2	19
334	Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 447-53	3.2	113
333	A validated gas chromatographic-electron impact ionization mass spectrometric method for methylenedioxyamphetamine (MDMA), methamphetamine and metabolites in oral fluid. <b>2006</b> , 835, 90-9		38

332	3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. <b>2007</b> , 189, 407-24	179
331	MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. <b>2006</b> , 187, 467-75	69
330	Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and its derivatives. <b>2006</b> , 3, 326-36	9
329	Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. <b>2006</b> , 31, 339-50	47
328	Plasma drug concentrations and physiological measures in 'dance party' participants. <b>2006</b> , 31, 424-30	46
327	Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions. <b>2006</b> , 20, 245-56	18
326	Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls. <b>2006</b> , 2, 111-149	24
325	Performance Enhancement and Adverse Consequences of MDMA. <b>2006</b> , 25, 47-59	4
324	Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. <b>2006</b> , 96, 678-85	188
323	Analysis of MDMA and its metabolites in urine and plasma following a neurotoxic dose of MDMA. <b>2007</b> , 31, 138-43	11
322	Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermoregulation and pharmacokinetics in male monkeys. <b>2007</b> , 35, 1840-5	39
321	MDMA and Other Club Drugs <b>2007</b> ,	1
320	Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. <b>2007</b> , 852, 450-8	29
319	A PET study of effects of chronic 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on serotonin markers in Göttingen minipig brain. <b>2007</b> , 61, 478-87	20
318	Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines. <b>2007</b> , 152, 1121-30	21
317	Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?. <b>2007</b> , 21, 467-80	31
316	The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. <b>2008</b> , 102, 15-24	32
315	A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). <b>2007</b> , 29, 288-300	44

314	Interpretation of oral fluid tests for drugs of abuse. <b>2007</b> , 1098, 51-103	118
313	Bioanalytical procedures for determination of drugs of abuse in blood. <b>2007</b> , 388, 1415-35	83
312	Effects of MDMA on blood glucose levels and brain glucose metabolism. <b>2007</b> , 34, 916-25	15
311	Development and validation of a liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human meconium. <b>2008</b> , 867, 194-204	33
310	The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. <b>2008</b> , 197, 263-78	36
309	Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers. <b>2008</b> , 197, 465-74	36
308	In vivo study on the roles of cytochrome P450 enzymes for metabolism of 3,4-methylenedioxymethamphetamine (Ecstasy) in rats. <b>2008</b> , 26, 52-57	1
307	Conjugates of p-hydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine in blood obtained from methamphetamine and 3,4-methylenedioxymethamphetamine users: analysis by LC-MS-MS. <b>2008</b> , 26, 58-65	16
306	Cardiac oxidative stress determination and myocardial morphology after a single ecstasy (MDMA) administration in a rat model. <b>2008</b> , 122, 461-9	35
305	Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver. <b>2008</b> , 8, 3906-18	43
304	Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. <b>2008</b> , 1139, 151-63	32
303	Review article: amphetamines and related drugs of abuse. <b>2008</b> , 20, 391-402	65
302	Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). <b>2008</b> , 230, 117-25	21
301	Estimation of neuronal numbers in rat hippocampus following neonatal amphetamine exposure: a stereology study. <b>2008</b> , 30, 495-502	15
300	On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats. <b>2008</b> , 54, 885-900	18
299	(+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks. <b>2008</b> , 55, 1121-30	23
298	Effect of chronic ethanol exposure on the hepatotoxicity of ecstasy in mice: an ex vivo study. <b>2008</b> , 22, 910-20	19
297	Memory and mood during the night and in the morning after repeated evening doses of MDMA. <b>2008</b> , 22, 895-903	15

296	Elimination half-lives of benzoylecgonine and MDMA in an apprehended driver. <b>2008</b> , 32, 197-8	3
295	Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. <b>2008</b> , 327, 38-44	30
294	Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram. <b>2008</b> , 33, 1192-205	21
293	The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. <b>2008</b> , 36, 2345-54	80
292	Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain. <b>2008</b> , 324, 284-91	38
291	Brain imaging in nonhuman primates: insights into drug addiction. <b>2008</b> , 49, 89-102	20
290	Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats. <b>2008</b> , 38, 314-24	35
289	The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. <b>2008</b> , 3, 1852-60	85
288	Determination of selected stimulants in urine for sports drug analysis by solid phase extraction via cation exchange and means of liquid chromatography-tandem mass spectrometry. <b>2008</b> , 14, 135-43	18
287	Developmental effects of 3,4-methylenedioxymethamphetamine: a review. <b>2008</b> , 19, 91-111	51
286	Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. <b>2008</b> , 28, 432-40	53
285	Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 320-32	3.2 86
284	The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. <b>2008</b> , 28, 523-9	42
283	Poisonings. <b>2008</b> , 1453-1474	
282	Ecstasy (MDMA): efeitos farmacológicos e tóxicos, mecanismo de ação e abordagem clínica. <b>2008</b> , 35, 96-103	7
281	Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. <b>2009</b> , 55, 454-62	28
280	Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. <b>2009</b> , 37, 1448-55	27
279	Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (ecstasy) intoxication: an event-related fMRI study. <b>2009</b> , 34, 1641-8	36

278	On the mechanisms underlying 3,4-methylenedioxymethamphetamine toxicity: the dilemma of the chicken and the egg. <b>2009</b> , 60, 119-29	19
277	The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. <b>2009</b> , 37, 2212-20	27
276	The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers. <b>2009</b> , 37, 1152-6	21
275	Methylenedioxymethamphetamine (Ecstasy) decreases neutrophil activity and alters leukocyte distribution in bone marrow, spleen and blood. <b>2009</b> , 16, 191-200	10
274	Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. <b>2009</b> , 16, 2661-805	59
273	Determination of 4-hydroxy-3-methoxymethamphetamine as a metabolite of methamphetamine in rats and human liver microsomes using gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry. <b>2009</b> , 33, 266-71	4
272	Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. <b>2009</b> , 37, 2163-70	62
271	Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA). <b>2009</b> , 241, 339-47	19
270	Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes. <b>2009</b> , 9, 30-8	25
269	MDMA: on the translation from rodent to human dosing. <b>2009</b> , 204, 375-8	46
268	Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma. <b>2009</b> , 393, 1607-17	13
267	Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. <b>2009</b> , 22, 1205-11	35
266	Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. <b>2009</b> , 190, 54-60	16
265	Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). <b>2009</b> , 88, 257-96	35
264	P.6.c.007 Association between opioid receptor availability and anxiety in healthy controls but not in substance dependence. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, S653-S654	1.2
263	P6.c.008 Pharmacogenetic modulation of neurocognitive deficits in MDMA users: The role of catechol-O-methyltransferase, serotonin transporter SERT and 5HT2A polymorphisms. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, S654	1.2
262	P.6.c.009 Psychiatric co-morbidity among patients with amphetamine and methamphetamine dependence in Malaysia. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, S654-S655	1.2
261	4-Hydroxy-3-methoxymethamphetamine glucuronide as a phase II metabolite of 3,4-methylenedioxymethamphetamine: enzyme-assisted synthesis and involvement of human hepatic uridine 5'-diphosphate-glucuronosyltransferase 2B15 in the glucuronidation. <b>2009</b> , 57, 472-5	15

260	Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 367-73	3.2	16
259	Mice in ecstasy: advanced animal models in the study of MDMA. <b>2010</b> , 11, 421-33		5
258	Chemistry, pharmacology, and metabolism of emerging drugs of abuse. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 544-9	3.2	55
257	Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage. <b>2010</b> , 11, 434-43		44
256	Recreational drugs, 3,4-Methylenedioxymethamphetamine(MDMA), 3,4-methylenedioxyamphetamine (MDA) and diphenylprolinol, inhibit neurite outgrowth in PC12 cells. <b>2010</b> , 35, 375-81		13
255	Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation. <b>2010</b> , 48, 695-708		29
254	Serotonergic Hallucinogens. <b>2010</b> , 585-602		1
253	Identification and quantitation of 3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy) in human urine by 1H NMR spectroscopy. Application to five cases of intoxication. <b>2010</b> , 194, 103-7		18
252	Involvement of mitochondrial/lysosomal toxic cross-talk in ecstasy induced liver toxicity under hyperthermic condition. <i>European Journal of Pharmacology</i> , <b>2010</b> , 643, 162-9	5.3	32
251	Synthesis of fatty acid amides of catechol metabolites that exhibit antiobesity properties. <b>2010</b> , 5, 1781-7		7
250	Gas chromatography-ion trap mass spectrometry method for the simultaneous measurement of MDMA (ecstasy) and its metabolites, MDA, HMA, and HMMA in plasma and urine. <b>2010</b> , 878, 815-22		15
249	Mechanisms mediating the ability of caffeine to influence MDMA ("Ecstasy")-induced hyperthermia in rats. <b>2010</b> , 160, 860-77		31
248	Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. <b>2010</b> , 1187, 316-40		136
247	Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. <b>2010</b> , 24, 155-64		24
246	Differential roles of phase I and phase II enzymes in 3,4-methylenedioxymethamphetamine-induced cytotoxicity. <b>2010</b> , 38, 1105-12		25
245	Stimulating Stuff: The Pathological Effects of Cocaine and Amphetamines on the Cardiovascular System. <b>2010</b> , 10, 251-255		2
244	Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice. <b>2010</b> , 1, 366-80		14
243	Intermittent prenatal MDMA exposure alters physiological but not mood related parameters in adult rat offspring. <b>2010</b> , 206, 299-309		12

242	21-year-old woman with palpitations and vomiting. <b>2010</b> , 85, e61-4	
241	Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. <b>2011</b> , 50, 319-29	24
240	Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. <b>2011</b> , 58, 92-101	19
239	3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. <b>2011</b> , 203, 82-91	12
238	Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. <b>2011</b> , 202, 120-8	21
237	The influence of genetic and environmental factors among MDMA users in cognitive performance. <b>2011</b> , 6, e27206	36
236	Behavioral effects of MDMA ('ecstasy') on adult zebrafish. <b>2011</b> , 22, 275-80	45
235	Method of simultaneous stir bar sorptive extraction of phenethylamines and THC metabolite from urine. <b>2011</b> , 36, 523-9	5
234	Review: The neuropathology of drug abuse. <b>2011</b> , 37, 118-34	114
233	Pill content, dose and resulting plasma concentrations of 3,4-methylenedioxymethamphetamine (MDMA) in recreational 'ecstasy' users. <b>2011</b> , 106, 1293-300	45
232	Induction of glutathione synthesis and conjugation by 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dihydroxymethamphetamine (HHMA) in human and rat liver cells, including the protective role of some antioxidants. <b>2011</b> , 289, 175-84	10
231	Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol). <b>2011</b> , 213, 745-56	13
230	Recently abused Etketo derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. <b>2011</b> , 29, 73-84	50
229	Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. <b>2011</b> , 46, 603-14	25
228	Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine metabolites 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach. <b>2011</b> , 39, 1998-2002	16
227	Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. <b>2011</b> , 57, 1748-56	22
226	A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity. <b>2011</b> , 31, 193-205	22
225	Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. <b>2012</b> , 26, 419-28	31



224	Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. <b>2012</b> , 26, 408-18	16
223	Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. <b>2012</b> , 27, 605-13	18
222	Date-Rape Drugs with Emphasis on GHB. <b>2012</b> , 355-434	1
221	MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?. <b>2012</b> , 3, 235	52
220	Chiral drug analysis using mass spectrometric detection relevant to research and practice in clinical and forensic toxicology. <b>2012</b> , 1269, 122-35	50
219	Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). <b>2012</b> , 7, e47599	40
218	Toxicity of amphetamines: an update. <b>2012</b> , 86, 1167-231	296
217	Neonatal citalopram treatment inhibits the 5-HT depleting effects of MDMA exposure in rats. <b>2012</b> , 3, 12-21	4
216	Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA). <b>2012</b> , 212, 38-47	4
215	Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. <b>2012</b> , 166, 1523-36	49
214	Drugs of Abuse (Including Designer Drugs). <b>2012</b> , 429-463	
213	Methylenedioxymethamphetamine (Ecstasy, MDMA). <b>2012</b> , 126-155	2
212	Analysis of Illicit Drugs in Human Biological Samples by LC-MSn. <b>2012</b> , 349-398	2
211	Simultaneous enantiomeric determination of MDMA and its phase I and phase II metabolites in urine by liquid chromatography-tandem mass spectrometry with chiral derivatization. <b>2012</b> , 404, 2427-35	14
210	LC-MS in Drug Bioanalysis. <b>2012</b> ,	3
209	The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. <b>2012</b> , 37, 1192-203	335
208	Effects of alcohol (BAC 0.5) and ecstasy (MDMA 100 mg) on simulated driving performance and traffic safety. <b>2012</b> , 222, 377-90	40
207	Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain. <i>European Journal of Pharmacology</i> , <b>2012</b> , 674, 337-44	5-3 22

206	Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. <b>2012</b> , 83, 131-8	21
205	Interaction of 3,4-methylenedioxymethamphetamine and methamphetamine during metabolism by in vitro human metabolic enzymes and in rats. <b>2012</b> , 57, 1008-13	11
204	Effects of MDMA (ecstasy) and two of its metabolites on rat embryos in vitro. <b>2012</b> , 34, 57-65	3
203	Ecstasy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. <b>2012</b> , 67, 1021-4	16
202	Ecstasy intoxication as an unusual cause of epileptic seizures in young children. <b>2013</b> , 172, 1547-50	7
201	Determination of the role of calcium on instability of neurotoxic metabolite of ecstasy by HPTLC-mass. <b>2013</b> , 21, 9	3
200	Chiral separation of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers using batch chromatography with peak shaving recycling and its effects on oxidative stress status in rat liver. <b>2013</b> , 73, 13-7	7
199	Roles of 3,4-methylenedioxymethamphetamine (MDMA)-induced alteration of connexin43 and intracellular Ca(2+) oscillation in its cardiotoxicity. <b>2013</b> , 310, 61-72	6
198	Schizophrenia-like disruptions of sensory gating by serotonin receptor stimulation in rats: effect of MDMA, DOI and 8-OH-DPAT. <b>2013</b> , 112, 71-7	5
197	Cytotoxic effects of amphetamine mixtures in primary hepatocytes are severely aggravated under hyperthermic conditions. <b>2013</b> , 27, 1670-8	17
196	Ecstasy-associated hyponatremia: why are women at risk?. <b>2013</b> , 28, 2206-9	21
195	Reply to 'MDMA can increase cortical levels by 800% in dance clubbers' Parrott et al. <b>2013</b> , 27, 115-6	4
194	The agony with ecstasy: lessons from a recent rave. <b>2013</b> , 28, 259-61	9
193	Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile. <b>2013</b> , 344, 479-88	19
192	Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA. <b>2013</b> , 16, 1383-94	18
191	Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. <b>2014</b> , 9, e99002	50
190	Mechanisms of Action of Different Drugs of Abuse. <b>2014</b> ,	
189	The involvement of secondary neuronal damage in the development of neuropsychiatric disorders following brain insults. <b>2014</b> , 5, 22	21

188	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. <b>2014</b> , 17, 527-40		50
187	The Neuropathology of Drug Abuse. <b>2014</b> , 169-202		1
186	Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, $\gamma$ -hydroxybutyric acid. <b>2014</b> , 103, 3310-5		1
185	Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. <b>2014</b> , 171, 83-91		29
184	Toxic Ingestions. <b>2014</b> , 695-727		
183	Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity. <b>2014</b> , 139, 162-73		4
182	Effects of MDMA on the Human Nervous System. <b>2014</b> , 475-497		3
181	Nephrotoxic effects of designer drugs: synthetic is not better!. <b>2014</b> , 10, 314-24		36
180	Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. <b>2014</b> , 42, 119-25		27
179	Emergence and properties of spice and bath salts: a medicinal chemistry perspective. <b>2014</b> , 97, 9-19		60
178	Baths salts, spice, and related designer drugs: the science behind the headlines. <b>2014</b> , 34, 15150-8		111
177	Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1773-83	1.2	12
176	Mixtures of 3,4-methylenedioxymethamphetamine (ecstasy) and its major human metabolites act additively to induce significant toxicity to liver cells when combined at low, non-cytotoxic concentrations. <b>2014</b> , 34, 618-27		14
175	Anesthesia for Trauma. <b>2014</b> ,		2
174	Modeling chronic brain exposure to amphetamines using primary rat neuronal cortical cultures. <b>2014</b> , 277, 417-34		5
173	Nephrotoxic effects of common and emerging drugs of abuse. <b>2014</b> , 9, 1996-2005		66
172	Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. <b>2014</b> , 822, 37-50		16
171	An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine. <b>2014</b> , 28, 231-9		5

170	Methamphetamine and MDMA: Safe Drugs of abuse. <b>2014</b> , 4, 34-38		2
169	Maternal MDMA administration in mice leads to neonatal growth delay. <b>2014</b> , 39, 33-9		10
168	Substance Abuse: Hallucinogen- and MDMA-Related Disorders. <b>2015</b> , 1480-1506		1
167	Inhibition of Cytochrome P450 Enzymes. <b>2015</b> , 177-259		7
166	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1637-49	1.2	19
165	"Addicted to Euphoria": The History, Clinical Presentation, and Management of Party Drug Misuse. <b>2015</b> , 120, 205-33		11
164	Cognitive Enhancement. <b>2015</b> ,		
163	Social cognition. <b>2015</b> , 228, 271-303		14
162	Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. <b>2015</b> , 43, 1864-71		16
161	Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma. <b>2015</b> , 7, 592-602		11
160	Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. <b>2015</b> , 40, 61-87		197
159	A Paediatric Case of Acute Respiratory Distress Syndrome following Toxicity due to Ecstasy. <b>2016</b> , 23, 238-241		
158	Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. <b>2016</b> , 11, e0150955		5
157	Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. <b>2016</b> , 3, 481-8		122
156	Human Pharmacology of Mephedrone in Comparison with MDMA. <b>2016</b> , 41, 2704-13		108
155	Elimination half-life of alpha-pyrrolidinovalerophenone in an acute non-fatal intoxication. <b>2016</b> , 54, 531-2		6
154	[The current aspects of the use of ecstasy/MDMA in France]. <b>2016</b> , 71, 553-562		8
153	Clinical applications of hallucinogens: A review. <b>2016</b> , 24, 229-68		90

152	Myocardial bridging and ecstasy: A fatal combination involving a 22year-old male. <b>2016</b> , 220, 835-6	3
151	GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. <b>2017</b> , 41, 100-106	17
150	Abuse potential of methylenedioxyamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors. <b>2016</b> , 233, 3031-9	10
149	Linear pharmacokinetics of 3,4-methylenedioxypropylamphetamine (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <b>2016</b> , 21, 339-47	76
148	Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics?. <b>2016</b> , 261, 137-47	8
147	A Metabolomics Study of Retrospective Forensic Data from Whole Blood Samples of Humans Exposed to 3,4-Methylenedioxyamphetamine: A New Approach for Identifying Drug Metabolites and Changes in Metabolism Related to Drug Consumption. <b>2016</b> , 15, 619-27	29
146	Evaluation of drug incorporation into hair segments and nails by enantiomeric analysis following controlled single MDMA intakes. <b>2016</b> , 408, 545-56	21
145	Inhibition potential of 3,4-methylenedioxyamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. <b>2016</b> , 243, 48-55	9
144	MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. <b>2016</b> , 64, 237-49	53
143	Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 232-238 <sup>1,2</sup>	28
142	Pharmacogenomics of abused drugs. <b>2017</b> , 117-133	0
141	Hyperpyrexia. 335-342	
140	Studies on Para-Methoxymethamphetamine (PMMA) Metabolite Pattern and Influence of CYP2D6 Genetics in Human Liver Microsomes and Authentic Samples from Fatal PMMA Intoxications. <b>2017</b> , 45, 1326-1335	3
139	Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. <b>2017</b> , 19, 1767-1778	23
138	Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats. <b>2017</b> , 32, 137-145	3
137	Comparison of 3 Derivatization Methods for the Analysis of Amphetamine-Related Drugs in Oral Fluid by Gas Chromatography-Mass Spectrometry. <b>2017</b> , 12, 1177390117727533	9
136	Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model. <b>2017</b> , 25, 16	3
135	Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites. <b>2017</b> , 47, 505-514	2

134	MDMA-Induced Dissociative State not Mediated by the 5-HT Receptor. <b>2017</b> , 8, 455	9
133	Monoamine Transporter and Receptor Interaction Profiles of Synthetic Cathinones. <b>2018</b> , 97-115	3
132	Synthetic Cathinones. <b>2018</b> ,	1
131	Melatonin in plant morphogenesis. <b>2018</b> , 54, 3-24	17
130	Key interindividual determinants in MDMA pharmacodynamics. <b>2018</b> , 14, 183-195	11
129	Studies with psychedelic drugs in human volunteers. <b>2018</b> , 142, 116-134	15
128	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. <b>2018</b> , 235, 709-717	2
127	Antemortem and postmortem influences on drug concentrations and metabolite patterns in postmortem specimens. <b>2018</b> , e1297	7
126	Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions. <b>2018</b> , 38, 632-638	32
125	The Detection of Novel Stimulants in Oral Fluid from Users Reporting Ecstasy, Molly and MDMA Ingestion. <b>2018</b> , 42, 544-553	19
124	Bioanalytical methods for determining ecstasy components in biological matrices: A review. <b>2018</b> , 108, 323-346	12
123	Pharmacodynamic Evaluation: Drug Dependency and Addiction. <b>2018</b> , 1-35	
122	E-cigarettes-An unintended illicit drug delivery system. <b>2018</b> , 192, 98-111	65
121	Substances of Abuse and Hallucinogenic Activity: The Dopaminergic Pathway - Focus on Cocaine and Amphetamine-type Stimulants. <b>2018</b> , 3-16	
120	Hallucinations in Psychoses and Affective Disorders. <b>2018</b> ,	1
119	Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. <b>2018</b> , 235, 3137-3148	64
118	Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. <b>2018</b> , 8, 8236	18
117	The psychostimulant (R)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. <b>2018</b> , 138, 282-291	16

116	A Study on Photostability of Amphetamines and Ketamine in Hair Irradiated under Artificial Sunlight. <b>2018</b> , 8,	6
115	Acute MDMA and Nicotine Co-administration: Behavioral Effects and Oxidative Stress Processes in Mice. <b>2018</b> , 12, 149	4
114	MDMA toxicity: management of acute and life-threatening presentations. <b>2018</b> , 27, 616-622	7
113	Neurotoxicology and drug-related disorders. <b>2017</b> , 145, 181-192	3
112	A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics. <b>2019</b> , 236, 881-890	19
111	MDMA-Associated Liver Toxicity: Pathophysiology, Management, and Current State of Knowledge. <b>2019</b> , 30, 232-248	7
110	Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. <b>2019</b> , 33, 831-841	15
109	Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. <b>2019</b> , 51, 108-117	8
108	MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma. <b>2019</b> , 39, 307-320	15
107	Metabolomics predicts the pharmacological profile of new psychoactive substances. <b>2019</b> , 33, 347-354	16
106	Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. <b>2019</b> , 236, 939-952	32
105	MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder: Implications for Social Work Practice and Research. <b>2020</b> , 48, 421-430	2
104	Cognitive consequences of 3,4-methylenedioxymethamphetamine use. <b>2020</b> , 165-177	
103	Speeding: a review of self-reported effects of amphetamine-type stimulants (ATS). <b>2020</b> , 28, 82-90	2
102	Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients. <b>2020</b> , 40, 32-44	10
101	Numerical Analysis of Time-Dependent Inhibition by MDMA. <b>2020</b> , 48, 1-7	1
100	Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. <b>2020</b> , 237, 431-442	4
99	Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments. <b>2020</b> , 49, 356	0

98 Psychedelics as a novel approach to treating autoimmune conditions. **2020**, 228, 45-54

14

97 Central nervous system stimulants. **2020**, 227-238

96 What Are Club Drugs and NPS and Why Are They Important?. **2020**, 3-4

95 A Brief History of NPS Production and Distribution. **2020**, 5-10

94 Classification Framework for Club Drugs and NPS. **2020**, 11-12

93 The Clinical Challenge of Club Drugs and NPS. **2020**, 13-22

92 Stimulant Drugs: Introduction. **2020**, 23-30

91 Stimulant Drugs: Cocaine. **2020**, 31-36

90 Stimulant Drugs: Amphetamine-Type Stimulants. **2020**, 37-37

89 Stimulant Drugs: Synthetic Cathinones. **2020**, 54-60

88 Depressant Drugs: Introduction. **2020**, 61-61

87 Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL). **2020**, 62-70

86 Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS. **2020**, 71-77

85 Depressant Drugs: Benzodiazepine NPS. **2020**, 78-80

84 Depressant Drugs: Ketamine and Its Analogues. **2020**, 81-88

83 Synthetic Cannabinoid Receptor Agonists (SCRAs). **2020**, 89-98

82 Hallucinogens. **2020**, 99-106

81 Stimulant Drugs: Methamphetamine. **2020**, 38-45



80	Stimulant Drugs: MDMA and Drugs with Similar Effects. <b>2020</b> , 46-53		
79	Concluding Remarks. <b>2020</b> , 107-108		
78	Index. <b>2020</b> , 124-130		
77	Introduction. <b>2020</b> , 1-2		
76	Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects. <b>2020</b> , 52, 258-282		4
75	Methamphetamine administration increases hepatic CYP1A2 but not CYP3A activity in female guinea pigs. <b>2020</b> , 15, e0233010		5
74	Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. <b>2020</b> , 13, 655-670		11
73	Drinking to death: Hyponatraemia induced by synthetic phenethylamines. <b>2020</b> , 212, 108045		9
72	Sexual Risk Behaviors among African Americans Who Use MDMA (Molly/Ecstasy): Implications for HIV Prevention. <b>2020</b> , 35, 282-292		0
71	MDMA interactions with pharmaceuticals and drugs of abuse. <b>2020</b> , 16, 357-369		10
70	Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. <b>2020</b> , 33, 161-170		11
69	Mephedrone and MDMA: A comparative review. <b>2020</b> , 1735, 146740		10
68	Pharmacological Mechanisms Involved in Sensory Gating Disruption Induced by (±)-3,4-Methylenedioxymethamphetamine (MDMA): Relevance to Schizophrenia. <b>2020</b> , 10,		1
67	The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants. <b>2020</b> , 208, 107772		2
66	Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 271-281	3-2	4
65	Neuropathology of Drug Abuse. <b>2021</b> ,		
64	Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. <b>2021</b> , 35, 512-536		2
63	The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. <b>2021</b> , 14, 901-910		6

62	Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects. <b>2021</b> , 377, 398-406		4
61	A case study on MDMA. Two fatal cases involving young adults. 1-11		
60	Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and mechanisms. <i>European Journal of Pharmacology</i> , <b>2021</b> , 903, 174156	5:3	1
59	Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4-methylenedioxymethamphetamine users. <b>2021</b> , e2811		0
58	Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. <b>2021</b> , 39, 2120-2133		1
57	Pharmacology of Commonly Abused Drugs. <b>2010</b> , 11-28		2
56	Addiction to Hallucinogens, Dissociatives, Designer Drugs and [Legal Highs] <b>2015</b> , 567-596		2
55	Amphētamines et dīvīš. <b>2012</b> , 455-505		2
54	Amnšie antfgrade consēctive ^ lābsorption de MDMA et dālcōol: ^ propos dūn cas. <b>2012</b> , 24, 23-27		2
53	Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study. <b>2020</b> , 8, 21		9
52	Effect of MDMA-Induced Axotomy on the Dorsal Raphe Forebrain Tract in Rats: An In Vivo Manganese-Enhanced Magnetic Resonance Imaging Study. <b>2015</b> , 10, e0138431		6
51	Have you seen Molly? A review of Molly in primary literature. <b>2014</b> , 4, 231-235		7
50	[Biochemical, pharmacological and toxic effects of n-metil 3,4-methylenedioxyamphetamine--"ecstasy"]. <b>2005</b> , 62, 467-75		
49	Neurochemistry of Drug Abuse. <b>2006</b> , 429-558		
48	Neurobiology of 3,4-Methylenedioxymethamphetamine (MDMA, or ""Ecstasy""). <b>2007</b> , 119-142		
47	Hallucinogens. <b>2008</b> , 313-366		
46	Procedures Pertaining to Hypothermia and Hyperthermia. <b>2010</b> , 1235-1258		
45	Pharmacogētīque. <b>2012</b> , 73-98		

44	Substance Abuse in Trauma and the Anesthesia Care Provider. <b>2014</b> , 433-445		
43	Cocaine, Methamphetamine, MDMA, and Heroin. <b>2015</b> , 595-605		
42	Renal/Metabolic Consequences of Drug/Alcohol Use. <b>2015</b> , 1655-1667		
41	MDMA. <b>2016</b> , 1-20		
40	MDMA. <b>2018</b> , 551-565		
39	Investigation of MDMA Inhibitory Effect on CytochromeP450 3A4 in Isolated Perfused Rat Liver Model Using Tramadol. <i>Advanced Pharmaceutical Bulletin</i> , <b>2021</b> , 11, 530-536	4.5	
38	Hallucinogens as Therapeutic Agents: Past, Present, and Future. <b>2021</b> , 1-12		
37	Pharmacodynamic Evaluation: Drug Dependency and Addiction. <b>2020</b> , 127-161		
36	Club Drugs and Novel Psychoactive Substances. <b>2020</b> ,		
35	Basic Substance Characteristics and Neuropathological Findings in Drug Abusers. <b>2021</b> , 23-87		
34	Addiction of Hallucinogens, Dissociatives, Designer Drugs and "Legal Highs" Update on Potential Therapeutic Use. <b>2021</b> , 259-279		1
33	Ecstasy (MDMA) and its effects on kidneys and their treatment: a review. <i>Iranian Journal of Basic Medical Sciences</i> , <b>2016</b> , 19, 1151-1158	1.8	7
32	MDMA to Treat PTSD in Adults. <i>Psychopharmacology Bulletin</i> , <b>2021</b> , 51, 125-149	0.9	
31	Psychedelic medicines for mood disorders: current evidence and clinical considerations. <i>Current Opinion in Psychiatry</i> , <b>2022</b> , 35, 22-29	4.9	2
30	Lack of evidence for positive reinforcing and prosocial effects of MDMA in pair-housed male and female rats. <i>European Journal of Pharmacology</i> , <b>2021</b> , 913, 174646	5.3	2
29	Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 696133	5	2
28	Drug and MDMA Interactions Implications for Public Health. <b>2022</b> , 1-26		
27	The promise of psychedelic research. <i>Future Drug Discovery</i> ,	2	1

- 26 Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,β-DEPEA and DPIA.. *European Neuropsychopharmacology*, **2022**, 59, 9-22 1.2 0
- 25 Trust and Psychopharmacology. **2021**, 338-368
- 24 Neuromolecular Level of Trust. **2021**, 313-386
- 23 Toward a positive psychology of psychoactive drug use. *Drugs: Education, Prevention and Policy*, 1-14 1.2
- 22 Life-Threatening 3,4-Methylenedioxyamphetamine (MDMA) Usage. **2022**, 1-10
- 21 Data\_Sheet\_1.docx. **2018**,
- 20 Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results.. *Journal of Neuropsychiatry and Clinical Neurosciences*, **2022**, appineuropsych21080213<sup>2,7</sup> 1
- 19 A review on the mitochondrial toxicity of Ecstasy (3,4-methylenedioxymethamphetamine, MDMA). *Current Research in Toxicology*, **2022**, 3, 100075 2.7
- 18 Evidence for altered neural activity patterns after MDMA-assisted therapy in adults with chronic and severe post-traumatic stress disorder: a pilot study.
- 17 3,4-Methylenedioxymethamphetamine (MDMA) and Synaptic Dopamine. **2022**, 1-19
- 16 MDMA for the Treatment of Negative Symptoms in Schizophrenia. *Journal of Clinical Medicine*, **2022**, 11, 3255 5.1
- 15 Grundlegende Substanzmerkmale und neuropathologische Befunde bei Drogenkonsumenten. **2022**, 23-90 0
- 14 Brain Concentrations of MDPV and its Metabolites in Male Rats: Relationship to Pharmacodynamic Effects. **2022**, 28, 2653-2663 1
- 13 Drug and MDMA Interactions Implications for Public Health. **2022**, 2243-2268 0
- 12 3,4-Methylenedioxymethamphetamine (MDMA) and Synaptic Dopamine. **2022**, 2195-2213 0
- 11 Life-Threatening 3,4-Methylenedioxyamphetamine (MDMA) Usage. **2022**, 2215-2223 0
- 10 A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. 13, 0
- 9 MDMA administration attenuates hippocampal IL-1β immunoreactivity and subsequent stress-enhanced fear learning: An animal model of PTSD. **2022**, 26, 100542 0

- 8 Hallucinogens as Therapeutic Agents: Past, Present, and Future. **2022**, 975-986 ○
- 7 Blood Analysis for Traditional Drugs of Abuse. **2023**, 356-364 ○
- 6 Psychedelic-Assisted Therapy for People with Eating Disorders. ○
- 5 Voltammetric Responses of a CYP2D6-Based Biosensor to 3,4-methylenedioxymethamphetamine (MDMA) and the Synthetic Cathinone  $\alpha$ -pyrrolidinopentiophenone ( $\alpha$ -PVP).. **2022**, 7, ○
- 4 Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans. **2022**, 23, 14636 2
- 3 Rumors of Psychedelics, Psychotropics and Related Derivatives in Vachellia and Senegalia in Contrast with Verified Records in Australian Acacia. **2022**, 11, 3356 ○
- 2 Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. 13, ○
- 1 Validated portable device for the qualitative and quantitative electrochemical detection of MDMA ready for on-site use. **2023**, 190, 108693 ○